SEP 23, 2021 1:30 PM PDT

The FDA approves the first and only oral treatment for a certain non-small cell lung cancer.

WRITTEN BY: J. Bryce Ortiz

Last week, the United States Food and Drug Administration (FDA) granted approval for the first oral therapy to treat a certain type of difficult-to-treat lung cancer. Lung cancer is the most commonly diagnosed cancer in the world, with over 2 million new diagnoses per year. Additionally, it is the leading cause of cancer-related deaths worldwide. Depending on the severity of the cancer there are various treatment regimens that include surgery, chemotherapy, and radiation therapy. Unfortunately, in some patients the disease continues to progress during or after these treatments. However, recent clinical trials have revealed promising data that the newly approved drug, mobocertinib (Exkivity, Takeda Pharmaceutical Company), can be used to combat treatment resistant lung cancer. 

Mobocertinib was designed to treat a specific type of treatment resistant lung cancer called non-small cell lung cancer (NSCLC). NSCLC is the most prominent form of lung cancers as it comprises around 85% of all lung cancer cases. Because of its high incidence and death rate, NSCLCs have been well studied and many of the genetic changes that lead to this type of lung cancer have been outlined. Among these genetic changes, mutations in a gene called epidermal growth factor receptor (EGFR) are common in NSCLCs. Targeting these mutations to treat or prevent NSCLC has been well studied, but discovering effective treatments for the mutations has proven elusive.  As Pasi A. Jänne, MD, PhD of Dana Farber Cancer Institute said, “EGFR [mutated non-small cell lung cancer] is an underserved cancer that we have been unable to target effectively with traditional [medications].” However, in preclinical and clinical studies, researchers found that mobocertinib works by preventing mutations to the EGFR gene which can help slow the spread of the cancer and the progression of the disease. 

Data presented by Takeda at the 57th American Society of Clinical Oncology Annual meeting provided clinical trial evidence of the effectiveness of mobocertinib in treating NSCLC patients with EGFR mutations. The data show that patients who were treated with the drug showed an improved survivability compared to patients who were treated with different medications. The FDA approved the medication based on these results and the drug is the first and only approved oral therapy that is designed specifically for NSCLC patients with EFGR mutations. The approval of this drugs is important milestone for patients with NSCLC and fulfills a critical need in providing therapy for this difficult-to-treat cancer.

 

Sources: FDACA: A Cancer Journal for CliniciansTakedaNatureCancer Discovery

About the Author
PhD in Neuroscience
Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
MAR 10, 2022
Drug Discovery & Development
Drug Equipped with Iron Sensor Halts Cancer Tumor Growth
MAR 10, 2022
Drug Equipped with Iron Sensor Halts Cancer Tumor Growth
A modified version of an FDA-approved drug can halt tumor growth driven by mutations in the RAS gene, which are notoriou ...
MAR 18, 2022
Drug Discovery & Development
In drug development studies, sleep is an important and overlooked vital sign
MAR 18, 2022
In drug development studies, sleep is an important and overlooked vital sign
Today is World Sleep Day, a celebration of sleep that aims to bring awareness to the importance of sleep as a found ...
MAR 22, 2022
Drug Discovery & Development
Medical Marijuana May Be Overhyped for Pain, Anxiety, Depression
MAR 22, 2022
Medical Marijuana May Be Overhyped for Pain, Anxiety, Depression
Claims about medical marijuana treating multiple mental health and neurological disorders may be overhyped, according to ...
MAR 30, 2022
Drug Discovery & Development
Universal Flu Vaccine Shows Promise in Mice
MAR 30, 2022
Universal Flu Vaccine Shows Promise in Mice
Just one dose of a new vaccine candidate may protect against multiple strains of flu. The corresponding research was pub ...
APR 01, 2022
Cannabis Sciences
Effects of Having a Medical Cannabis Card on Symptom Management
APR 01, 2022
Effects of Having a Medical Cannabis Card on Symptom Management
A recent study published in Psychiatry found differences in cannabis use habits and symptom management among the two mai ...
MAY 15, 2022
Microbiology
A Virus Was Used to Cure an Antibiotic-Resistant Lung Infection
MAY 15, 2022
A Virus Was Used to Cure an Antibiotic-Resistant Lung Infection
In a clinical first, reported in Cell, researchers used viruses that infect bacteria, called bacteriophages or phages fo ...
Loading Comments...